– USA, CA – Adobe (Nasdaq:ADBE) today announced the appointment of David “Dave” A. Ricks to its board of directors, effective April 12, 2018. The addition of Ricks expands Adobe’s board of directors from 10 to 11 members.

Ricks currently serves as Chief Executive Officer of Eli Lilly and Company and became chairman of the Eli Lilly and Company board of directors in June 2017. Prior to January 2017, Ricks served as president of Lilly Bio-Medicines. From 2009 to 2012, he served as president of Lilly USA, the company’s largest affiliate. Ricks served as president and general manager of Lilly China, operating in one of the world’s fastest-growing emerging markets, from 2008 to 2009. He was general manager of Lilly Canada from 2005 to 2008, after roles as director of Pharmaceutical Marketing and National Sales director in Canada. Ricks joined Eli Lilly and Company in 1996 as a business development associate and held several management roles in U.S. marketing and sales before moving to Lilly Canada. He holds a Bachelor of Science from Purdue University and an M.B.A. from Indiana University.

“We are thrilled to welcome Dave to the Adobe board. We expect to benefit greatly from his experience and counsel as we seek to continue Adobe’s momentum and to execute on our strategy to empower people to create and transform how businesses compete,” said Shantanu Narayen, chairman, president and CEO, Adobe.

About Adobe

Adobe is changing the world through digital experiences.

For more information : http://www.adobe.com

- DisclaimerNews, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.

here the original post =>

Comments are closed.